Vimian appoints Patrik Eriksson as new CEO
Vimian Group AB (publ) (“Vimian”) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare.
Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista (NYSE:NVST). Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organisations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics.
“The Board of Directors is very pleased to welcome Patrik Eriksson as the new CEO of Vimian. He is a highly experienced and appreciated leader with relevant sector background and an impressive track record of strong value creation in multiple decentralised and global organisations. Over the past three years, we have tripled the size of the company and aim to continue on the same trajectory. We are convinced that Patrik has the experience and skills required to lead the execution of our strategy of organic growth and strategic acquisitions”, says Gabriel Fitzgerald, Chairman of the Board.
“I am excited to join Vimian and continue building a global leader in attractive niches of animal health with unmet medical needs. The company has a compelling vision to improve animal health through science and technology, and I look forward to working together with the team to create significant value and help millions of animals around the world to a better life”, says Patrik Eriksson.
As part of the remuneration package, Patrik Eriksson has been offered to acquire 81,905 warrants at market price and 4,095 employee stock options as part of the long-term incentive program adopted at the annual general meeting 2023 (LTI 2023). Furthermore, Patrik Eriksson has been offered to acquire 550,000 call options in Vimian at market price from Fidelio Vet Holding AB, Vimian’s largest shareholder. The call options are exercisable into shares after five years, in three tranches with an exercise price corresponding to SEK 26.54 subject to an annual step-up in exercise price of 10, 15 and 20 percent, respectively, starting on 21 December 2023.
Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.